Physician profile
Christopher A Brian
NPI 1982789335
$3,168.18
in general payments reported to CMS, 2019-2025
22 companies · $657 in 2025
The $657 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $90.05 · 2021: $162 · 2022: $726 · 2023: $564 · 2024: $500 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,721.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $700.63 | 2022-2025 | |
| Pfizer INC. | $500.24 | 2019-2025 | |
| Amgen INC. | $329.61 | 2019-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $287.28 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.50 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $193.47 | 2021-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $185.21 | 2022-2025 | Camzyos, Eliquis |
| Abiomed | $129.81 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $122.29 | 2024-2025 | Farxiga, Lokelma |
| Janssen Pharmaceuticals, INC | $115.79 | 2019-2023 | Xarelto |
| Abbott Laboratories | $92.46 | 2021-2023 | Cardiomems |
| Amarin Pharma, INC. | $57.95 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $31.87 | 2024-2025 | Amvuttra |
| Biocompatibles, INC. | $30.45 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $24.46 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $21.79 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Esperion Therapeutics, INC. | $21.55 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.22 | 2025 | |
| Bridgebio Pharma, INC. | $18.05 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $17.68 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.33 | 2023 | Lifevest |
| Cook Medical LLC | $13.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Brian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.